797 related articles for article (PubMed ID: 21178137)
1. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.
Chao MP; Jaiswal S; Weissman-Tsukamoto R; Alizadeh AA; Gentles AJ; Volkmer J; Weiskopf K; Willingham SB; Raveh T; Park CY; Majeti R; Weissman IL
Sci Transl Med; 2010 Dec; 2(63):63ra94. PubMed ID: 21178137
[TBL] [Abstract][Full Text] [Related]
2. Elimination of Cancer Cells in Co-Culture: Role of Different Nanocarriers in Regulation of CD47 and Calreticulin-Induced Phagocytosis.
Hassan EM; McWhirter S; Walker GC; Martinez-Rubi Y; Zou S
ACS Appl Mater Interfaces; 2023 Jan; 15(3):3791-3803. PubMed ID: 36632842
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
4. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.
Anderson KL; Snyder KM; Ito D; Lins DC; Mills LJ; Weiskopf K; Ring NG; Ring AM; Shimizu Y; Mescher MF; Weissman IL; Modiano JF
Melanoma Res; 2020 Apr; 30(2):147-158. PubMed ID: 31205227
[TBL] [Abstract][Full Text] [Related]
5. Anti-leukemia effect associated with down-regulated CD47 and up-regulated calreticulin by stimulated macrophages in co-culture.
Hassan EM; Walker GC; Wang C; Zou S
Cancer Immunol Immunother; 2021 Mar; 70(3):787-801. PubMed ID: 32995942
[TBL] [Abstract][Full Text] [Related]
6. CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis.
Morrissey MA; Kern N; Vale RD
Immunity; 2020 Aug; 53(2):290-302.e6. PubMed ID: 32768386
[TBL] [Abstract][Full Text] [Related]
7. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia.
Melo Garcia L; Barabé F
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944878
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.
Nigro A; Ricciardi L; Salvato I; Sabbatino F; Vitale M; Crescenzi MA; Montico B; Triggiani M; Pepe S; Stellato C; Casolaro V; Dal Col J
Front Immunol; 2019; 10():3135. PubMed ID: 32082304
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
11. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
[TBL] [Abstract][Full Text] [Related]
12. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
[TBL] [Abstract][Full Text] [Related]
13. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Theruvath J; Menard M; Smith BAH; Linde MH; Coles GL; Dalton GN; Wu W; Kiru L; Delaidelli A; Sotillo E; Silberstein JL; Geraghty AC; Banuelos A; Radosevich MT; Dhingra S; Heitzeneder S; Tousley A; Lattin J; Xu P; Huang J; Nasholm N; He A; Kuo TC; Sangalang ERB; Pons J; Barkal A; Brewer RE; Marjon KD; Vilches-Moure JG; Marshall PL; Fernandes R; Monje M; Cochran JR; Sorensen PH; Daldrup-Link HE; Weissman IL; Sage J; Majeti R; Bertozzi CR; Weiss WA; Mackall CL; Majzner RG
Nat Med; 2022 Feb; 28(2):333-344. PubMed ID: 35027753
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy.
Zhang YR; Luo JQ; Zhang JY; Miao WM; Wu JS; Huang H; Tong QS; Shen S; Leong KW; Du JZ; Wang J
Small; 2020 Nov; 16(46):e2004240. PubMed ID: 33107142
[TBL] [Abstract][Full Text] [Related]
15. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R
Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259
[TBL] [Abstract][Full Text] [Related]
17. CD47 is not Over-Expressed in Fibrolamellar Hepatocellular Carcinoma.
Cooney T; Wei MC; Rangaswami A; Xu L; Sage J; Hazard FK
Ann Clin Lab Sci; 2017 Aug; 47(4):395-402. PubMed ID: 28801364
[TBL] [Abstract][Full Text] [Related]
18. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
He Y; Bouwstra R; Wiersma VR; de Jong M; Jan Lourens H; Fehrmann R; de Bruyn M; Ammatuna E; Huls G; van Meerten T; Bremer E
Nat Commun; 2019 Feb; 10(1):533. PubMed ID: 30710089
[TBL] [Abstract][Full Text] [Related]
19. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT
Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209
[No Abstract] [Full Text] [Related]
20. Decreased CD47 expression during spontaneous apoptosis targets neutrophils for phagocytosis by monocyte-derived macrophages.
Lawrence DW; King SB; Frazier WA; Koenig JM
Early Hum Dev; 2009 Oct; 85(10):659-63. PubMed ID: 19815354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
